# Functional analysis of ESM1 by shRNA-mediated knockdown of its expression in papillary thyroid cancer cells

## TL;DR

This study shows that reducing ESM1 in thyroid cancer cells decreases their growth and spread, suggesting ESM1 could be a target for treatment.

## Contribution

The novel contribution is identifying ESM1 as a driver of papillary thyroid cancer progression through functional knockdown experiments.

## Key findings

- ESM1 expression was significantly higher in papillary thyroid cancer tissues compared to normal tissues.
- Knockdown of ESM1 reduced cancer cell proliferation, migration, and invasion in vitro.
- ESM1 knockdown significantly decreased mRNA and protein levels in thyroid cancer cells.

## Abstract

Endothelial specific molecule-1 (ESM1) is implicated as an oncogene in multiple human cancers. However, the function of ESM1 in papillary thyroid cancer (PTC) is not well understood. The current study aimed to investigate the effect of ESM1 on the growth, migration, and invasion of PTC to provide a novel perspective for PTC treatment.

The expression levels of ESM1 in PTC tissues form 53 tumor tissue samples and 59 matching adjacent normal tissue samples were detected by immunohistochemical analysis. Knockdown of ESM1 expression in TPC-1 and SW579 cell lines was established to investigate its role in PTC. Moreover, cell proliferation, apoptosis, wound healing, and transwell assays were conducted in vitro to assess cell proliferation, migration and invasion.

The findings revealed that ESM1 expression was significantly higher in PTC tissues than that found in paraneoplastic tissues (P<0.0001). Knockdown of ESM1 expression inhibited the proliferation, migration, and invasion of TPC-1 and SW579 cells in vitro. Compared with the control group, the mRNA and protein levels of ESM1 in PTC cells were significantly reduced following knockdown of its expression (P<0.01). In addition, ESM1-knockdown cells indicated decreased proliferation and decreased migratory and invasive activities (P<0.01, P<0.01, P<0.001, respectively).

ESM1 was identified as a major gene in the occurrence and progression of PTC, which could increase the proliferation, migration, and invasion of PTC cells. It may be a promising diagnostic and therapeutic target gene.